Back to search results

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

Abroad (travel likely)RecruitingPHASE3

Conditions

Pulmonary Hypertension Due to Lung Disease (Disorder)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Arizona Pulmonary Specialists, Ltd., Scottsdale, Arizona, United States

  • Tampa General Hospital, Tampa, Florida, United States

    Contact: Study coordinator (Elisabeth Ballans) · eballans@tgh.org

  • Northwestern University, Chicago, Illinois, United States

  • St. Vincent Cardiovascular Research Institute, Indianapolis, Indiana, United States

    Contact: Study coordinator (Morgan Arnold) · morgan.arnold@ascension.org · 317-338-9337

  • Summit Health, Bend, Oregon, United States

    Contact: Study coordinator (Madison Cox) · mklinskicox@summithealth.com · 541-706-5339

  • Ordensklinikum Linz GmbH, Linz, Austria

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Assistance Publique Hopitaux De Paris, Le Kremlin-Bicêtre, France

  • Universitätsklinikum Giessen und Marburg - Standort Giessen, Giessen, Germany

  • University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Medizinische Hochschule Hannover, Hanover, Germany

  • Pauls Stradinš Clinical University Hospital, Riga, Latvia

  • Unidade Local De Saude De Almada-Seixal E.P.E., Almada, Portugal

  • Hospital Del Mar, Barcelona, Spain

  • Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom

  • University Hospitals Plymouth NHS Trust - Derriford Hospital, Plymouth, United Kingdom

View source on ClinicalTrials.gov(opens in a new tab)